RPL-301 is a gene-modified cell therapy commercialized by Rocket Pharmaceuticals, with a leading Phase I program in Anemia. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of RPL-301’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for RPL-301 is expected to reach an annual total of $37 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RPL-301 Overview
RPL-301 is under development for the treatment of pyruvate kinase deficiency. The therapeutic candidate constitutes patient-derived immature bone marrow cells (called CD34+) genetically modified with a lentivirus to express pyruvate kinase (PKLR) enzyme. It is administered through intravenous route.
Rocket Pharmaceuticals Overview
Rocket Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel gene therapies. The company’s pipeline products include LV RP-L102 Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, AAV RP-A501 Danon Disease, AAV RP-A601 PKP2-ACM and AAV BAG3-DCM. Its LV RP-L102 Fanconi Anemia, a gene therapy product that treats bone marrow that reduces the production of blood cells or promotes the production of faulty blood cells; Leukocyte Adhesion Deficiency-I for immune system and Pyruvate Kinase Deficiency, which targets a red blood cell autosomal recessive disorder that results in a chronic non-spherocytic hemolytic anemia; AAV RP-A501 Danon Disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy that treats heart diseases. Rocket Pharmaceuticals is headquartered in Cranbury, New Jersy, the US.
The operating loss of the company was US$259.7 million in FY2023, compared to an operating loss of US$224.3 million in FY2022. The net loss of the company was US$245.6 million in FY2023, compared to a net loss of US$221.9 million in FY2022.
For a complete picture of RPL-301’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
